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The most recent report released by the World Health Organization (WHO) disclosed that tuberculosis (TB) is now the leading cause of human mortality by an infectious disease 1 
D-cycloserine (DCS) is an orally available, broad-spectrum antibacterial that was isolated in 1955 from a Streptomyces species 3 . It was shown in 1960 to inhibit both the Staphylococcus aureus alanine racemase (AR) and D-ala-D-ala ligase (DAL), enzymes involved in the synthesis
of the peptidoglycan component of bacterial cell walls, and was the first antibiotic whose mechanism of action was shown to be due to enzyme inhibition 4 . DCS has been shown to be an irreversible inhibitor of bacterial D-amino acid transaminase 5 , and the structure of the covalent pyridoxal 5'-phosphate (PLP)-DCS complex has been determined 6 . The structure revealed that the DCS ring was intact and aromatic. This finding was also confirmed for the inactivation of γ-aminobutyric (GABA) aminotransferase by L-cycloserine (LCS) 7 . Structures of the DCS-and LCS-inhibited forms of dialkylglycine decarboxylase 8 and of the LCS-inhibited forms of methionine γ-lyase 9 have also been reported.
DCS is presently used almost exclusively as a second-line drug to treat multidrugresistant TB (MDR-TB) 10, 11 , due to its toxicity related to its activity as a mammalian neuronal NMDA receptor agonist and an increase in the levels of inhibitory neurotransmitters 12, 13 . The 4 targets of DCS in M. tuberculosis were proposed to be similar to those in S. aureus; the PLPdependent AR and DAL 11 . Early studies using genetic selection revealed that resistance to DCS was the result of mutations in the alanine-glycine-D-serine permease and the D-ala-D-ala ligase 14 . Overexpression of the gene encoding alanine racemase was shown to confer resistance to DCS in Mycobacterium smegmatis 15 . DCS was subsequently shown to be a slow, tight-binding inhibitor of the M. tuberculosis D-ala-D-ala ligase 11 . Two reports of metabolomic profiling of DCS-treated mycobacterial cell extracts both concluded that D-ala-D-ala ligase was the primary, and lethal, target of DCS 16, 17 . A recent study demonstrated that clinical strains with low-level resistance to DCS mapped to mutations in the ald gene, encoding alanine dehydrogenase 18 .
Branched-chain amino acids are biosynthesized in M. tuberculosis in a manner similar to other eubacteria and by enzymes that have all been annotated in the genome 19 . We have previously reported the three-dimensional structure of the ilvE-encoded (Rv2210c) branchedchain aminotransferase (BCAT) from M. tuberculosis (MtIlvE) 20 . The PLP-dependent enzyme was crystallized in complex with pyridoxamine 5'-phosphate (PMP) and is a homodimer. MtIlvE catalyzes the L-glutamate-dependent amination of α-ketoisocaproate, α-keto-methyloxopentanoic acid and α-ketoisovalerate to generate the three branched-chain amino acids (BCAAs) L-leucine, L-isoleucine and L-valine 21 . The enzyme is essential for growth under multiple growth conditions 22, 23 . 
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In the present study, we examined the ability of DCS and LCS to inhibit MtIlvE. Our results show that both isomers inhibit the enzyme in a time-and concentration-dependent manner. However, LCS binds more tightly, and inhibits more rapidly, than does DCS and is a better inhibitor of mycobacterial growth. We crystallized the DCS-inhibited enzyme, and solved the structure to 1.7 Å. The structure of the enzyme-bound PMP-DCS adduct reveals that the DCS ring is intact and aromatic, as previously observed. Using absorbance spectra and mass spectrometry, we identified the MtIlvE LCS-PMP final complex as identical to that of the MtIlvE DCS-PMP complex. Based on our findings, we propose a mechanism of inhibition of MtIlvE by each of the cycloserine isomers based on stereochemical, kinetic and structural evidence.
RESULTS AND DISCUSSION

Inactivation of MtIlvE by DCS and LCS
Mechanism-based inhibitors are a class of substrate analogs that lead to irreversible inhibition. Enzyme inactivation is caused by an initial chemical step identical to that normally occurring in catalysis followed by subsequent steps resulting in the formation of a stable deadend complex, creating an irreversible protein-inhibitor complex 26, 27 . The highly conserved catalytic mechanism of PLP-dependent enzymes makes them particularly amenable to mechanism-based inhibitor design and enzyme inactivation 6, [26] [27] [28] [29] [30] . Due to their involvement in so many essential biological processes, a number of PLP-dependent enzymes have been targeted as potential drug targets 3, [11] [12] [13] .
The pre-incubation of MtIlvE with different concentrations of either DCS or LCS led to a decrease of enzymatic activity over time ( Figure 1 LCS is also a significantly better inhibitor than DCS of the PLP-dependent serine palmitoyltransferase from Sphingomonas paucimobili, an enzyme that catalyzes the condensation of L-serine with palmitoyl-CoA in the biosynthetic pathway of sphingolipids 29 . LCS has been exploited in several model systems 8, 33 , including seizure models, due to its ability to increase intracerebral GABA levels 34 .
We tested other PLP-dependent enzyme inactivators including propargylglycine, an inhibitor of cystathionine γ-synthase 28 ; gabaculine, an inhibitor of GABA aminotransferase and ornithine decarboxylase
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; and difluoromethylornithine (DFMO), the inhibitor of ornithine decarboxylase 35 . The pre-incubation of MtIlvE with 10 mM of each of these inhibitors for over one hour did not lead to any decrease in the activity of MtIlvE (data not shown). It has been 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 7 previously shown that gabapentin, a potent inhibitor of the hBCATc, has no effect on the activity (Table S1 ). Figure S1 ). However, previous reports of the concerted 1,3-prototropic shift mechanism of MtIlvE 21 and the structural studies presented below, suggest the formation of a stable, aromatic PMP-isoxazole adduct.
Electrospray ionization-mass spectrometric analysis of MtIlvE DCS and LCS complexes
The overnight incubation of
UV-visible analysis of MtIlvE Inactivated by DCS and LCS
Enzymes containing the PLP cofactor can be kinetically analyzed using UV-VIS 21 . In the presence of 1 mM DCS, a similar pattern is observed ( Figure 3A) . order decrease in the absorbance at times less than 8-10 minutes is not observed, while a twoexponential fit conforms to all the data. The kinetic and stereochemical interpretation of these differences will be discussed below.
Overall Structure of MtIlvE-PLP-DCS
MtIlvE incubated with DCS until complete inactivation of the enzyme was achieved was crystallized, and the structure of MtIlvE-PMP-DCS was solved to 1.7 Å. Data collection and refinement statistics are summarized in Table 1 The MtIlvE structure displays the characteristic type IV fold of PLP-dependent enzymes 20 , with each monomer consisting of a small and a large domain that define the two active sites at the domain interfaces. The first domain includes both N-and C-terminal residues (residues 34-173 and 362-368) forming three α-helices and eight β-strands while the second domain is composed of residues 182 to 362, displaying nine β-strands and three α-helices ( Figure 4) . A rigid α-helix between residues E340 and R354 connects the two domains. A flexible loop (residues 173-182) should also link both domains, but no electron density was observed and the loop was not built into the MtIlvE-PMP-DCS model.
As previously observed, the N-terminal portion of the protein is highly disordered and electron density is only observable from H35 in monomer A and Y34 in monomer B in the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 11
MtIlvE-PMP-DCS structure. Additionally, a loop consisting of residues G174 to I181, which connect the two domains of MtIlvE, is poorly resolved in this structure. This linker loop is located near the active site and is highly flexible due to the presence of two glycine residues (G179-G180). This linker loop has been shown to play a significant role in the entrance and exit of the substrates/products 39, 40 . In contrast to aspartate aminotransferase, that exhibits a conformational change involving the small domain closing onto the active site upon binding of the substrate [41] [42] [43] [44] , only the linker loop between the small and large domains moves to close the active site in BCAT enzymes 39, 40, 45 .
Cys196 disulfide bond
In the MtIlvE-PMP structure, Tremblay et al. observed cysteine residues (Cys196) that were located at the homodimer interface 3.6 Å away from its identical symmetry-mate residue 20 .
There was no evidence in that structure that the two cysteine residues form a disulfide bond, but based on their separation, it was clear that they could under oxidative conditions. In contrast, the MtIlvE-PMP-DCS structure exhibits clear 2Fo-Fc electron density supporting the presence of a disulfide linkage between the Cys196 residues from each monomer. The distance between the Sγ atoms in the intersubunit disulfide bond is 2.05 Å, an appropriate bond length distance. The formation of an intersubunit disulfide bond had previously been hypothesized to increase the stability of the MtIlvE dimer under the oxidative conditions observed within the macrophages 20 .
Cysteine residues have been shown to play a significant role in the regulation of catalytic activity of hBCATm [45] [46] [47] . A C 315 XXC 318 motif is conserved among all mammalian BCAT enzymes and the formation of a C315-C318 disulfide bond leads to a loss in activity of hBCATm. The cysteine residues involved in the disulfide bridge in the MtIlvE-PMP-DCS structure are 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 structurally located in a different region, and C196 is not a conserved residue among other BCAT enzymes ( Figure S3 ). The cycloserine ring appears tilted compared to the plane of the pyridine ring. The geometry indicates an sp 3 hybridization of the C4A atom, confirming the identity of the PMP form of the cofactor. Additionally, the five-membered ring is planar and is consistent with the presence of an aromatic, isoxazole ring. The cycloserine portion of the adduct makes polar interactions with residues within the active site. N2 forms a hydrogen bond (2.6 Å) with the Figure S4 ).
Enzyme interaction with PMP-cycloserine adduct
Mechanistic Analysis of the Inhibition of MtIlvE by DCS and LCS
The very different kinetic behavior of the two stereoisomers of cycloserine was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 electrostatically with R101 and is on the "C5-phosphate" side of the PLP ring and the C4-αH is within 2.7 Å of K204 in a model of the precatalytic complex. Removal of the αH is expected to be fast from this complex, generating the ketimine intermediate, in which the orientation of the oxazolidine ring is now fixed due to the restricted rotation about the cofactor-inhibitor imine linkage. These two steps, external aldimine formation followed by deprotonation to generate the ketimine may be the rapid steps that are reported on in the early (<10 minutes) spectral traces of inactivation by LCS ( Figure 3B ). This argues that the final step, C5-H abstraction to generate the aromatized and stable 2-isoxazole adduct is slow from the LCS-generated ketimine.
In contrast, the time course of the UV-Vis changes accompanying DCS inhibition ( Figure   3A ) of MtIlvE suggest that the opposite stereochemistry is associated with changes in the relative rates of these same steps discussed above. DCS may bind initially in the "LCS orientation" with the C3 hydroxyl anion on the "C5-phosphate" side of the pyridoxal ring, but must ultimately rotate to allow for C4-αH removal by K204, placing the C3 hydroxyl anion on the "C3-hydroxyl" side of the pyridoxal ring. This is likely to make the formation of the precatalytic external aldimine conformation slower than with LCS. Proton abstraction, accompanied by a 1,3 prototropic shift generates the ketimine, which differs from the ketimine generated from LCS in the orientation of the oxazole ring and the positioning of the C5 protons. Proton abstraction from C5 of the oxazole ring leads to the final aromatized PMP-isoxazole covalent complex. Since the stereochemical differences are lost as a result of Cα-H abstraction, as are any rotational restrictions in the PMP-LCS and PMP-DCS adducts, it is unclear whether the crystallographically observed orientation of the ring for the PMP-DCS adduct ( Figure 5B ) is also not adopted by the PMP-LCS adduct after ring aromatization. robust activity of LCS against M. tuberculosis. While the current drug design principle of "one drug-one target" has been effective, perhaps "death by a thousand cuts" might be equally effective as an antibacterial therapeutic paradigm.
MATERIALS AND METHODS
Reagents: All chemicals were of analytical or reagent grade and did not undergo further purification. DCS and LCS were purchased from Sigma Aldrich. 
Expression and purification of MtIlvE: MtIlvE
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The reaction was initiated by the addition of aliquots from the inactivation mixture. All measurements were performed in duplicate at 25 °C using buffer A (50 mM Tris HCl, pH 8.0).
A percentage of the total activity in the absence of inhibitor or time zero was calculated.
Kitz and Wilson plots of ln % remaining activity versus time were linear 52 . All data points are from an average of duplicate or triplicate measurements, and all data were analyzed by nonlinear regression using the SigmaPlot software (Systat Software, Inc.) and fitting to equation 1 53 : (1) where, E(0) represents the activity prior to addition of the inhibitor, E(t) is the activity after addition of either DCS or LCS at time = t, k app is the inactivation rate at any inhibitor 
UV-visible spectroscopy of MtIlvE inhibition by DCS and LCS: MtIlvE was incubated with α-
ketoisocaproate for 60 minutes to ensure that all active sites of the enzyme were converted into the internal aldimine (Schiff-base) form. The protein was dialyzed against buffer A to remove excess PLP and leucine formed during the incubation. The concentration of PLP bound to the enzyme was determined using absorbance spectroscopy at a wavelength of 415 nm (Ɛ 415 = 4,900 M -1 .cm -1 ) as previously calculated 21 . UV-Vis time course experiments were carried out using 100 µM MtIlvE and the spectrophotometer was blanked with buffer A. One milliliter quartz cuvettes were used, and spectra from 550 to 240 nm were recorded upon the addition of 1 mM DCS or 0.5 mM LCS at different times. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 20
Source Argonne National Laboratory (APS-ANL, IL) at 0.97931 Å wavelength radiation.
Diffraction data were indexed, integrated and scaled to 1.7 Å using the XDS program package 55 .
Molecular replacement was carried out with the software Phaser-MR using PDB 3HT5 as the search model 20, 56 . Two molecules per asymmetric unit were observed. Using the solution obtained by molecular replacement, the refine tool available in the PHENIX suite was used to
perform rigid body refinement simulated annealing, positional and B-factor refinements 50 . The model was manually corrected using COOT 57 . Clear 2Fo-Fc and Fo-Fc electron density maps corresponding to a PLP-cycloserine adduct were observed. The geometric restraints of the PLPcycloserine adduct, represented by the three-letter code DCS, were determined using eLBOW (electronic Ligand Builder and Optimization Workbench) in PHENIX 58 . MOLPROBITY was used to assess the quality of the structure 59 . Two residues were observed in the disallowed region of the Ramachandran plot (V317 in each monomer). The structure was deposited in the Protein Data Bank (PDB accession code 5U3F). 
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